Another potent ATP-competitive TβRI inhibitor is LY3200882, which has shown a tolerable safety profile and early signs of antitumor efficacy for patients with advanced pancreatic cancer [139]. This evidence concerns the gene TGFBR1 and familial pancreatic carcinoma.